{
    "address": "Berzelius Vag 13",
    "city": "Solna",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4R29H123",
    "description": "InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 7 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn\u2019s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.",
    "employeeTotal": "7.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Pharmaceuticals",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Pharmaceuticals",
    "gsector": "Health Care",
    "gsubind": "Pharmaceuticals",
    "ipo": "2016-10-11",
    "isin": "SE0008966295",
    "logo": "https://finnhub.io/api/logo?symbol=INDEX.ST",
    "marketCapitalization": 779.8547,
    "naics": "Pharmaceutical and Medicine Manufacturing",
    "naicsNationalIndustry": "Pharmaceutical Preparation Manufacturing",
    "naicsSector": "Manufacturing",
    "naicsSubsector": "Chemical Manufacturing",
    "name": "InDex Pharmaceuticals Holding AB",
    "phone": "",
    "sedol": "BD60FH6",
    "shareOutstanding": 532.68765,
    "state": "STOCKHOLM",
    "ticker": "INDEX.ST",
    "weburl": "https://www.indexpharma.com/"
}